Investigational drug · Phase 2
CD25
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
118
Any phase or sponsor naming "CD25"
First trial start
2025
Mar 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CD25", any sponsor or status.
Conditions studied
As listed on its trial records.
- Presymptomatic Diabetes Type 1 (Stage 1)
- Diabetes Mellitus, Type I
- Diabetes Mellitus, Type 1
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "CD25" as an intervention, largest first.
- A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung CancerPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07217301 · 1,200 participants (planned) · Start Nov 26, 2025 · Primary completion Nov 1, 2028
Drug: TAK-928; Control Arm · For: IO Resistant Squamous and Nonsquamous NSCLC
Sites: Jonesboro, Arkansas; Fair Oaks, California; Fountain Valley, California · 50 sites in all
- Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrencePivotal-lookingTerminated
Nektar TherapeuticsIndustry
NCT04410445 · 765 participants · Start Jul 27, 2020 · Primary completion Sep 22, 2022
Drug: Bempegaldesleukin; Nivolumab · For: Melanoma; Melanoma Stage III; Melanoma Stage IV and 1 more
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Anaheim, California · 212 sites in all
Nektar TherapeuticsIndustry
NCT03729245 · 623 participants · Start Dec 18, 2018 · Primary completion Jan 7, 2022
Drug: bempegaldesleukin; sunitinib and 2 more · For: Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Sites: Anchorage, Alaska; Goodyear, Arizona; Little Rock, Arkansas · 96 sites in all
- "Cocktail" Therapy for Hepatitis B Related Hepatocellular CarcinomaPivotal-lookingStatus unknown
Yuehua HuangAcademic, hospital or other
NCT04317248 · 600 participants (planned) · Start Apr 1, 2020 · Primary completion Apr 30, 2022
Drug: Cyclophosphamide; Multiple Signals loaded Dendritic Cells Vaccine · For: Hepatocellular Carcinoma
Sites: Guangzhou, China · 4 sites in all
Rongrong LiuAcademic, hospital or other
NCT06657391 · 396 participants (planned) · Start Oct 1, 2024 · Primary completion Sep 30, 2027
Drug: recombinant humanized anti-CD25 monoclonal antibody · For: Transfusion Dependent Thalassemia
Sites: Maoming, China; Liuzhou, China; Nanning, China · 5 sites in all
Masonic Cancer Center, University of MinnesotaAcademic, hospital or other
NCT00176930 · 330 participants · Start Oct 2001 · Primary completion Dec 2019
Drug: Stem Cell Transplant; Cyclophosphamide and 3 more · For: Leukemia, Myeloid, Chronic; AML; Leukemia, Lymphocytic, Acute and 6 more
Sites: Minneapolis, Minnesota
- Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney TransplantationPivotal-lookingStatus unknown
University of KhartoumAcademic, hospital or other
NCT03789006 · 300 participants (planned) · Start Mar 21, 2018 · Primary completion Mar 21, 2022
Drug: Antithymocyte Immunoglobulin (Rabbit); Interleukin 2 Receptor Antagonist · For: Kidney Transplant Rejection
Sites: Khartoum, Sudan
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialPivotal-lookingNot yet recruiting
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT06620822 · 296 participants (planned) · Start Sep 30, 2024 · Primary completion Sep 30, 2026
Drug: IBI363; LM-108+Sintilimab and 2 more · For: Non Small Cell Lung Cancer
Sites: Shanghai, China
- Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal AllograftsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00933231 · 281 participants · Start Aug 17, 2009 · Primary completion May 11, 2015
Drug: tacrolimus; tacrolimus and 5 more · For: Kidney Transplantation
Sites: Calgary, Canada; Edmonton, Canada; Winnipeg, Canada · 13 sites in all
- Steroid Withdrawal in Pediatric Kidney Transplant RecipientsPivotal-lookingTerminated
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00023244 · 274 participants · Start Jan 2001 · Primary completion Jun 2005
Drug: Basiliximab; Cyclosporine and 5 more · For: End-Stage Renal Disease
Sites: Birmingham, Alabama; San Diego, California; Aurora, Colorado · 19 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- All-trans retinoic acid-driven immune remodeling in esophageal squamous cell carcinoma revealed by single-cell transcriptomics.
Yang T, Huang Y, Liu Y, et al. · Biochim Biophys Acta Mol Basis Dis 2027
- Immunophenotyping of Human Regulatory T-Cells from Peripheral Blood Mononuclear Cells.
Lopez-Ocasio M, Lin WC, Hockman SC, et al. · Methods Mol Biol 2027
- IL-15 trans-presentation at the innate-adaptive interface: mechanisms and translation in cancer immunotherapy.
Goldman CK · Oncoimmunology 2026
- The in utero experience of NOD fetuses imprints disposition of B- and T-cell populations, autoantibody patterns, and diabetes development.
Renman E, Lejon K · Autoimmunity 2026
- Exploring the causal links among immune cell characteristics and prostatitis: a bidirectional two-sample Mendelian randomization study.
Wang Y, Xue C, Xu Z, et al. · Aging Male 2026
- Role of LGALS9 and human milk oligosaccharides in modulating immune responses in food allergy: Insights from network pharmacology and molecular simulations.
Chen S, Ai K, Liu Y, et al. · Biochem Biophys Res Commun 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.